drugset / Trial / NCT01212627
Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer
Phase 1
Terminated
12 enrolled
Angela Taber MD
Memorial Hospital of Rhode Island · collabRhode Island Hospital · collabRoger Williams Medical Center · collabThe Miriam Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to evaluate the best dose, safety and side effects of ridaforolimus when given with cetuximab for patients with head and neck, lung and colon cancer that has progressed after initial therapy. A second purpose of this study is to gain preliminary information on whether the combination of ridaforolimus and cetuximab is helpful in treating patients with advanced head and neck cancer
Timeline
- Start
- 2010-09
- Primary completion
- 2012-12
- Completion
- 2013-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ridaforolimus | Small molecule | 10 mg | — |
| Subject | ridaforolimus | Small molecule | 20 mg | — |
| Subject | ridaforolimus | Small molecule | 30 mg | — |
| Subject | ridaforolimus | Small molecule | 40 mg | — |